Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. CBRS
3. FDX
4. USO
5. MU
6. SPY
7. KBH
8. HTZ
9. HON
10. JPM

Go back to Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study

Mizuho Securities Reiterates Buy Rating on Pfizer (PFE) After Speaking with Management

May 18, 2020 7:01 AM EDT

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $42.00 price target on Pfizer (NYSE: PFE) following a conference call with management. Pfizer released updated data on their Duchenne Muscular Dystrophy (DMD) candidate at ASGCT.

Divan's overall conclusion is unchanged in that the... More